Nasri Nahas – CEO, Biopôle
Nasri Nahas, CEO of Biopôle, shares his vision for one of Europe’s leading life sciences innovation parks and its evolving role within the national and international healthcare ecosystem. In this…
Company Profile
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as multiple sclerosis (MS), lymphoma and rheumatoid arthritis. In 2008, Biogen Idec’s total revenues grew 29 percent over 2007 to $4.1 billion. Biogen Idec is headquartered in Cambridge, Massachusetts, with international headquarters in Zug, Switzerland. They have additional offices in the US, Canada, Australia, Japan and throughout Europe. Biogen Idec has a direct commercial presence in 29 markets, a network of distribution partners in more than 70 additional markets and operations in several new markets, including Central/Eastern Europe, Brazil, China and India.
Contact Info
Biogen Idec Switzerland AG
Zählerweg 6
CH 6300 Zug
Switzerland
Phone: +41 41 728 7444
Fax: +41 41 728 7440
www.biogenidec.ch
International Headquarters
Biogen Idec International GmbH
Landis & Gyr-Strasse 3
CH 6300 Zug
Switzerland
Phone: +41 41 39 21700
Fax: +41 41 39 21710
www.biogenidec-international.com
Nasri Nahas, CEO of Biopôle, shares his vision for one of Europe’s leading life sciences innovation parks and its evolving role within the national and international healthcare ecosystem. In this…
Oliver Kuhn, CEO of Selectchemie, has had a diverse career spanning various sectors, starting in the financial industry before transitioning to healthcare. Under his leadership, Selectchemie has sharpened its strong…
Once a traditional Swiss pharmaceutical wholesaler, Unipharma has undergone a profound transformation into a globally oriented, strategy-driven partner for hospitals, pharmaceutical, and biotechnology companies. Under the leadership of CEO Simone…
Five decades since its founding, Helsinn has recently undergone one of the most consequential transformations in its history. Executive Chairman Riccardo Braglia and Group CEO Melanie Rolli reflect on a…
SkyCell is at the forefront of a fundamental shift in pharmaceutical logistics, where AI, real-time monitoring, and sustainability are no longer optional but essential. As pharmaceutical supply chains grow more…
The 2025 Davos World Economic Forum brought together business leaders from multiple industries to debate the challenges and issues facing the world today. The Pharma CEOs in attendance discussed critical…
Over the course of its 350-year history, Merck KGaA has expanded from its base in Darmstadt, Germany to establish a strong presence in various markets across the globe. Last year,…
The Women’s Brain Foundation, formerly the Women’s Brain Project, has evolved into a fully-fledged foundation dedicated to advancing research in gender precision medicine with a strong focus on brain health.…
The World Health Organisation has highlighted antimicrobial resistance (AMR) as one of the leading global public health and development threats today. AMR occurs when bacteria, viruses, fungi and parasites change…
Industry stakeholders are raising the alarm about access to innovative medicines in Switzerland. Do delays in market access compared to other countries in Europe not only threaten the health of…
Switzerland is the 22nd biggest country in Europe in terms of population yet plays host to a full 20 percent of the continent’s life science companies, with over 1,000 operational…
Intricacy, precision, and quality. These are bywords for Switzerland’s world-renowned watchmaking industry, but which could equally apply to its biopharmaceutical manufacturing footprint. As with top-end models from Rolex, Tag Heuer,…
See our Cookie Privacy Policy Here
